Fusion Antibodies plc is a early discovery partner located in Belfast, which develop and optimizes therapeutic and diagnostic antibodies. Working with early-stage Biotech’s, Fusion’s expertise, process frameworks, and development platforms, enables our clients to develop therapeutics within the most challenging modalities and diseases. Fusion guides them through early-stage antibody discovery, in the most efficient and effective way ensuring that the clients can achieve their goals
Fusion Antibodies provides a broad range of partnering opportunities in antibody generation, development, production, characterisation, and optimisation. Our capabilities include antigen expression, antibody production, purification, sequencing, and antibody humanisation. Fusion’s proprietary CDRx® and RAMP® platforms provide our partners with antibodies that have a superior probability of reaching the patients.
Since 2012, Fusion Antibodies has successfully developed over 275 antibodies for an international client base. The Company’s growth strategy is based on combining the latest technological advances with cutting edge science to deliver new discovery platforms, such as OptiMAL®, an unique Mammalian display service offering, that will enable Biotech companies to get to the clinic faster, with the optimal drug candidate. To know more
